Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool February 8, 2006 Stephen D. Simpson	Glaxo: Healthy Drugmaker Glaxo combines a huge sales force, a rich pipeline, and solid returns on capital. This company should get a thorough look from anyone putting new money into the pharma space.
The Motley Fool October 27, 2005 Stephen D. Simpson	A Balanced Attack for Glaxo A broad suite of drugs, a huge sales force, and a solid pipeline make GlaxoSmithKline an appealing pharmaceutical company. The problem for investors is that it's all valued into the stock.
The Motley Fool April 28, 2008 Brian Lawler	Glaxo Getting By Weakening currency barely redeems the pharmaceutical's Q1 numbers.
The Motley Fool February 14, 2005 Stephen D. Simpson	Glaxo Stays Above the Fray The British drugmaker looks to regain momentum this year. Investors who are comfortable with the general industry risks and are looking for a relatively "clean" pharmaceutical company should do some research on Glaxo shares.
The Motley Fool November 9, 2006 Brian Lawler	The Best Blue Chip for 2007: GlaxoSmithKline Here's a blue-chip pharma stock for your portfolio.
The Motley Fool February 8, 2008 Brian Lawler	Hold on to GlaxoSmithKline This might be a tough year for the big pharma company, but its pipeline makes it a keeper.
The Motley Fool April 27, 2006 Stephen D. Simpson	Glaxo's Story Still Worth Reading A good pipeline could keep GlaxoSmithKline's already-impressive shares rolling.
The Motley Fool April 28, 2005 Stephen D. Simpson	Glaxo Works to Stay on Track With FDA issues near resolution, Glaxo should continue its respectable growth trajectory. Investors looking at the pharmaceutical space would do well to at least consider this stock.
The Motley Fool February 22, 2010 Brian Orelli	Warning: Avandia Could Cause Drool Among Trial Lawyers An unintended side effect of Glaxo's Avandia might be excessive salivation among trial lawyers. A 342-page report by the Senate Finance Committee is painting the diabetes drug in a not-so-great light.
The Motley Fool April 24, 2006 Stephen D. Simpson	Novartis: A Good Story Repeated Whether sales were a little light or not, this is still a high-quality pharmaceutical company. The company not only has a good pipeline, but the valuation is still attractive without needing to make particularly aggressive assumptions.
The Motley Fool October 28, 2004 Bill Mann	Glaxo's Mild Depression The British drug maker sees increased generic competition for its anti-depressant drugs. Total constant currency sales slipped to $7.7 billion in the current quarter from $8.5 billion last year.
The Motley Fool April 29, 2010 Brian Orelli	Earnings Up 17%, but Here's Why You Should Be Worried One-time sales are no way to run a pharmaceutical business.
BusinessWeek March 6, 2006 Gene G. Marcial	Why Glaxo Looks More Robust Big pharma, besieged by generic rivals, is hardly a Street favorite. But GlaxoSmithKline may be an exception.
The Motley Fool July 28, 2005 Stephen D. Simpson	Glaxo Keeps It Going Despite missing sales from the depression franchise, Glaxo managed to post respectable quarterly results.
The Motley Fool November 26, 2007 Brian Lawler	Glaxo Goes Holiday Shopping The pharmaceutical giant snaps up another acquisition, privately held Reliant Pharmaceuticals, for $1.65 billion in cash, one of the largest pharma deals of the year.
The Motley Fool April 15, 2011 Brian Orelli	Shedding the Pounds Through Divestiture Glaxo plans to sell 19 OTC products.
The Motley Fool February 3, 2011 Owain Bennallack	Glaxo Sweetens a Bitter Pill The drugmaker reports a loss, but resumes share buybacks.
The Motley Fool July 25, 2008 Brian Lawler	Glaxo Changes Course Will a shift in strategy turn the drugmaker around?
The Motley Fool April 22, 2011 Sean Williams	Pharma's Most Perilous Pipelines Patent expirations expose weaknesses for these Wall Street darlings.
The Motley Fool February 12, 2004 Alyce Lomax	Depressing Year for Glaxo The pharmaceutical giant forecasts three lackluster quarters as copycats attack.
The Motley Fool October 18, 2005 Stephen D. Simpson	More Good News From Novartis This Swiss drug giant continues to post steady growth. Investors, take note.
The Motley Fool February 19, 2010 Brian Orelli	Breathe Deep. It Might Not Be That Bad. The FDA strikes down asthma drugs, but will doctors buy in?
The Motley Fool December 1, 2005 Brian Gorman	Glaxo Follows the Biotechs The company's new focus on cancer drugs looks like a good move. Investors, take note.
The Motley Fool June 14, 2007 Ryan Fuhrmann	Dueling Fools: GlaxoSmithKline Bear Glaxo is definitely a safe bet in the industry, and Avandia concerns have brought the share levels to even more reasonable levels. But investors can find the risk/reward trade-off even more compelling in other names.
The Motley Fool February 28, 2011 Brian Orelli	Pharma's Newest Acquisition Targets Share buybacks are in at big pharma companies. Does it mean that licensing deals are out?
The Motley Fool April 16, 2009 Brian Orelli	2 Virus Killers Are Better Than 1 Glaxo brings Pfizer under its HIV wing.
The Motley Fool October 23, 2008 Brian Orelli	Glaxo to Competitors: You're Cheaper Than We Are This big pharma has cash and it plans to use it.
The Motley Fool December 21, 2006 Ryan Fuhrmann	Dueling Fools: Merck Bear Rebuttal Yes, Merck is a good company, but investors can still do better.
The Motley Fool May 21, 2010 Brian Orelli	And You Thought Biotech Was High-Risk, High-Reward Large clinical trials make cardiovascular drugs risky, but the rewards are there, too.
The Motley Fool August 15, 2007 Billy Fisher	Adversity Continues for Avandia Avandia and Actos receive black box labels from the FDA. The two diabetes medications have been linked to an increase in heart failure.
The Motley Fool June 14, 2007 Ryan Fuhrmann	Dueling Fools: GlaxoSmithKline Bear Rebuttal There are better opportunities to use short-term pain and establish positions in pharmaceuticals with better long-term potential.
The Motley Fool June 15, 2009 Brian Orelli	Strange Bedfellows GlaxoSmithKline is teaming up with none other than its arch-nemesis, generic-drug maker Dr. Reddy's Laboratories, licensing more than 100 of their brands to sell in emerging markets.
The Motley Fool February 22, 2005 Charly Travers	Is Big Pharma a Bargain? While much of the drug sector is looking pretty tasty, Pfizer, with its attractive relative valuation, dominant marketing presence, and willingness to buy up blockbuster drugs, heads the list.
The Motley Fool April 10, 2008 Brian Lawler	Glaxo Angers the FDA GlaxoSmithKline announces that the FDA has sent it a warning letter regarding its failure to meet certain post-marketing requirements for Avandia.
The Motley Fool February 29, 2008 Brian Orelli	2007 Pharma Roundup How did big pharma do in 2007? With the drug sector earnings season winding down, now seems like a good time to take a look at how they fared and, more importantly, where they're headed.
The Motley Fool February 22, 2010 Brian Orelli	A Huge Business Wrapped Up in Tiny Packages Drug investors shouldn't forget about over-the-counter products.
The Motley Fool July 14, 2005 Stephen D. Simpson	These Swiss Don't Miss Aside from a hiccup in margins, Novartis' drug business continues to shine. This pharma is a solid middle-of-the-road play with reasonable valuation, a solid pipeline, and a not-so-secret weapon in its Sandoz generics business.
The Motley Fool May 1, 2008 Brian Lawler	Glaxo's Global Growth Gambit The pharmaceutical's new CEO has changes in mind.
The Motley Fool November 30, 2009 Brian Orelli	Making Money More Efficiently Drug companies shape up, and it shows in their margins.
Registered Rep. March 1, 2005 David A. Twibell	What Ails You? Investors who are wary of big pharma investments have good reasons to be. But this does not mean that the sector is to be avoided at all costs. Indeed, for savvy, well-informed investors, now might be a good time to jump in.
The Motley Fool March 26, 2009 Brian Orelli	Big Pharma's R&D Model Is Broken Bigger isn't always better.
The Motley Fool September 11, 2008 Brian Orelli	Glaxo's Not Gambling The pharmaceutical's deal for drug developer Cellzome is back-end loaded.
The Motley Fool November 30, 2010 Brian Orelli	A Witty Response to Pharma's R&D Dilemma According to GlaxoSmithKline CEO Andrew Witty, the pharmaceutical industry is a mess. That's the basic gist of his opinion piece in The Economist.
The Motley Fool April 27, 2006 Stephen D. Simpson	A Sluggish Bristol-Myers Squibb Generic erosion is going to chew away revenue and profits. Investors, at today's prices, there are just too many other better ideas to go after.
The Motley Fool October 28, 2009 Brian Orelli	Saved by Emerging Markets. Sort Of. GlaxoSmithKline's top line looks good, but the bottom is what counts.
The Motley Fool February 26, 2010 Brian Orelli	A Risky Deal, but at Least It's Cheap Glaxo licenses a preclinical compound from Regulus.
The Motley Fool June 13, 2008 Brian Lawler	Glaxo Gears Up a Blockbuster One of the pharmaceutical's top new compounds scores final EU approval.
The Motley Fool July 27, 2006 Stephen D. Simpson	AstraZeneca Needs a Rest The stock isn't too expensive, but it's no longer a bargain.
The Motley Fool January 19, 2006 Stephen D. Simpson	Novartis Marches On While reported profits are masked by some charges, this Swiss drug company is still delivering the goods. Throw in a solid pipeline and a reasonable valuation, and the stock could still be worth a look for new money in the pharmaceutical space.
The Motley Fool July 9, 2010 Brian Orelli	2 Days, 1 Blockbuster, Fate Unknown GlaxoSmithKline heads before a marathon two-day Food and Drug Administration advisory panel review of its diabetes drug Avandia.